Introduction: Bruton's tyrosine kinase inhibitor, ibrutinib, was recently approved for treatment-naïve, relapsed/refractory and del(17p)/TP53 mutated chronic lymphocytic leukemia (CLL). Discrepancies between clinical trials and routine healthcare are commonly observed in hematology-oncology. We aimed to evaluate the real-world clinical characteristics and drug-related toxicities of patients with CLL treated with ibrutinib in Portugal.Methods: We conducted a multicenter (13 institutions) retrospective observational study of 70 patients diagnosed with CLL that began treatment with ibrutinib between May 2014 and January 2017. We evaluated patient characteristics, biological features of the disease, previous therapy, toxicities, and overall survival (OS). All patients received ibrutinib as a single agent, all but 5 at an initial dose of 420 mg daily. Clinical data were analyzed using IBM® SPSS® Statistics version 22.0.Results: Median age of the cohort was 68 years (IQR: 63-74); 41 patients (58.6%) were male. Median CIRS score was 4 (2-6); ECOG performance status score was 0-1 in 90.5% and 2-4 in 9.5% of evaluable patients; 65.7% were staged as Rai III/IV and 61.4% as Binet C; 54.4% had del(17p) and 11.9% del(11q); 15.7% were treatment naïve; median number of previous lines of therapy for CLL was 2 (1-3); 50% were previously treated with fludarabine and 74.3% with rituximab-containing regimens.Median duration of Ibrutinib treatment was 7.7 months (3-15.5); median follow-up was 8.7 months (4-18.3). Adverse events (AEs) were identified in 87.1% of patients; 51.4% had severe AEs (SAEs -CTCAE
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.